1 / 13

Preparedness to Monitor Safety of the Pandemic (H1N1) 2009 Vaccines VRBPAC July 23, 2009

Preparedness to Monitor Safety of the Pandemic (H1N1) 2009 Vaccines VRBPAC July 23, 2009. Presented by Hector S. Izurieta CBER/FDA. 1. Pandemic (H1N1) 2009 Vaccine Potential Issues. New strain, monovalent vaccine Potential for use of novel adjuvants Large numbers of vaccinees expected

jaden
Download Presentation

Preparedness to Monitor Safety of the Pandemic (H1N1) 2009 Vaccines VRBPAC July 23, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preparedness to Monitor Safety of thePandemic (H1N1) 2009 VaccinesVRBPACJuly 23, 2009 Presented by Hector S. Izurieta CBER/FDA 1

  2. Pandemic (H1N1) 2009 Vaccine Potential Issues • New strain, monovalent vaccine • Potential for use of novel adjuvants • Large numbers of vaccinees expected • Most age and risk groups • Relatively rapid vaccine administration • Heightened public attention and expectation for robust safety surveillance • Expected increase in reporting of temporally-associated events regardless of causal association to vaccination (compared to seasonal vaccine)

  3. Adverse Event Monitoring • Improvements in passive surveillance (VAERS) for all events (data mining, timeliness of analysis) • Enhanced surveillance for pre-specified events identified by: • Pre-licensure safety data • Published literature • Post-licensure safety data with seasonal influenza vaccines • Accruing available international data on pandemic (H1N1) 2009 vaccines with and without adjuvants • Need for adaptable toolbox

  4. Strategy • Enhanced/more timely pharmacovigilance tools for: • Signal detection • Signal strengthening and verification • Confirmation of possible association • Increased communication/collaboration among U.S. agencies, and also internationally • Methods • Sharing of preliminary safety surveillance results • Signal validation and confirmation of potential associations

  5. Toolbox: Signal Detection

  6. Signal Strengthening, Verification and Confirmation

  7. Vaccine Safety Data Link (CDC)Timely Identification and Rapid Assessment Eight managed care organizations representing approximately 9 million US individuals Sequential Analytical methods Allows rapid assessment of pre-specified adverse events Simultaneous analysis with appropriate comparison group Requires accurate vaccination information linked to managed care database Outcome linked with exposure

  8. Other CDC Tools for Signal Strengthening and Verification • Emerging Infections Program (EIP) for special studies • Collaboration with the American Academy of Neurology (AAN) • Guillain Barre Syndrome (GBS) reporting • Field investigations • Adverse event clinical assessments - CISA (Clinical Immunization Safety Assessment)

  9. Development of capability for electronic safety monitoring using Medicare data: CMS-FDA pilot project, focused on pandemic preparedness, showed ability to use weekly Medicare data for potential vaccine safety monitoring Example of CBER/CMS collaboration: Rapid analysis of rare adverse event (AE) after flu vaccine in 2006.* Vaccinations AE Cases Per Million FDA-CMS Collaboration

  10. Pre-specified AEs Non-prespecified AEs Tier-1 AEs Tier-2 AEs Tier-3 AEs Retrospective cohorts to estimate background rates Phase 1: Prior to vax Bi/Weekly listings of cases and vaccine doses distributed Enhanced surveillance through RCA Data mining, other analyses Phase 2: During vax Positive signal (expert review) Scan Statistics to confirm the signal Positive signal Positive signal Self-controlled case series to verify the signal Phase 3: Post-vax Retrospective cohorts to estimate incidence rates of AEs during H1N1 vaccination season and to evaluate risk of AE following H1N1 vaccine DOD-FDA-CDC H1N1 Research Plan Flow Chart

  11. Considerations Regarding Vaccine Administration • Distribution and administration of vaccines likely to vary by state, city and county • usefulness for safety surveillance will vary • Linkage of vaccination data (exposure) to outcome data (medically attended event) is essential to capacity and timeliness for detection/evaluation of safety signals

  12. Summary • Pandemic preparedness has: • Enhanced capacity for timely signal detection, verification and confirmation • Strengthened collaboration and communication among government agencies and internationally • There is variability in data quality and timeliness • Timely availability of conclusive post-utilization safety data remains a challenge given: • Expected rapid vaccination period • Questions regarding vaccine distribution and recording • Rarity of expected adverse events

  13. Robert Ball Rickey Wilson Robert Wise Andrea Sutherland Claudia Vellozzi Michael McNeil Douglas Pratt Amy Groom Cunningham Fran Jeff Kelman Patrick Garman Dale Burwen Wei Hua Aysha Akhtar Sukhminder Sandhu Yandong Qiang Laura Polakowski Angela Eick Acknowledgements

More Related